Ionis Pharmaceuticals Overview
- Status
-
Public
- Employees
-
927
- Stock Symbol
-
IONS
- Investments
-
20
- Share Price
-
$32.68
- (As of Tuesday Closing)
Ionis Pharmaceuticals General Information
Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
Contact Information
Website
www.ionis.comCorporate Office
- 2855 Gazelle Court
- Carlsbad, CA 92010
- United States
Corporate Office
- 2855 Gazelle Court
- Carlsbad, CA 92010
- United States
Ionis Pharmaceuticals Stock Performance
As of 21-Jan-2025, Ionis Pharmaceuticals’s stock price is $32.68. Its current market cap is $5.16B with 158M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $32.68 | $31.43 | $31.40 - $52.49 | $5.16B | 158M | 1.43M | -$2.44 |
Ionis Pharmaceuticals Financials Summary
As of 30-Sep-2024, Ionis Pharmaceuticals has a trailing 12-month revenue of $803M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 5,682,455 | 6,475,002 | 4,607,971 | 3,591,922 |
| Revenue | 803,067 | 787,647 | 587,367 | 810,456 |
| EBITDA | (249,524) | (235,870) | (233,080) | (5,188) |
| Net Income | (358,811) | (366,286) | (269,722) | (28,597) |
| Total Assets | 3,081,099 | 2,990,072 | 2,533,876 | 2,611,690 |
| Total Debt | 1,446,654 | 1,453,539 | 1,369,195 | 1,251,050 |
Ionis Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ionis Pharmaceuticals Comparisons
Industry
Financing
Details
Ionis Pharmaceuticals Competitors (50)
One of Ionis Pharmaceuticals’s 50 competitors is Arrowhead Pharmaceuticals, a Corporation company based in Pasadena, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | ||||
| Moderna | Formerly VC-backed | Cambridge, MA | ||||
| Gilead Sciences | Formerly VC-backed | Foster City, CA | ||||
| Nektar Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA |
Ionis Pharmaceuticals Patents
Ionis Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240401061-A1 | Compounds and methods for reducing pln expression | Pending | 05-Apr-2023 | ||
| US-20240301411-A1 | Compounds and methods for reducing app expression | Pending | 17-Feb-2023 | ||
| US-20240325425-A1 | Allele-selective compounds and methods for modulating huntingtin expression | Pending | 17-Feb-2023 | ||
| US-20240124513-A1 | Compounds and methods for reducing mecp2 expression | Active | 23-Sep-2022 | ||
| US-12152052-B2 | Compounds and methods for reducing mecp2 expression | Active | 23-Sep-2022 | C07H21/04 |
Ionis Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ionis Pharmaceuticals Investments & Acquisitions (20)
Ionis Pharmaceuticals’s most recent deal was a Early Stage VC with Aro Biotherapeutics for . The deal was made on 23-Nov-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aro Biotherapeutics | 23-Nov-2021 | Early Stage VC | Drug Discovery | ||
| Bicycle Therapeutics | 09-Jul-2021 | PIPE | Drug Discovery | ||
| Akcea Therapeutics | 12-Oct-2020 | Merger/Acquisition | Biotechnology | ||
| Empirico | 20-Dec-2019 | Early Stage VC | Drug Discovery | ||
| Dynacure | 10-Nov-2017 | Early Stage VC | Drug Discovery |
Ionis Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
26.87 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,104
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
Ionis Pharmaceuticals Exits (13)
Ionis Pharmaceuticals’s most recent exit was on 09-Jul-2021 from Bicycle Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Bicycle Therapeutics | 09-Jul-2021 | Completed |
|
||
| Dynacure | 10-Nov-2017 | Completed |
|
||
| Dynacure | 01-Oct-2016 | Completed |
|
||
| Regulus Therapeutics | 04-Oct-2012 | Completed |
|
||
| Altair Therapeutics | 12-Nov-2009 | Early Stage VC | Completed |
|
Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Ionis Pharmaceuticals (Manufacturing and Marketing Rights of Ulefnersen) | Tokyo, Japan |
Ionis Pharmaceuticals FAQs
-
Where is Ionis Pharmaceuticals headquartered?
Ionis Pharmaceuticals is headquartered in Carlsbad, CA.
-
What is the size of Ionis Pharmaceuticals?
Ionis Pharmaceuticals has 927 total employees.
-
What industry is Ionis Pharmaceuticals in?
Ionis Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Ionis Pharmaceuticals a private or public company?
Ionis Pharmaceuticals is a Public company.
-
What is Ionis Pharmaceuticals’s stock symbol?
The ticker symbol for Ionis Pharmaceuticals is IONS.
-
What is the current stock price of Ionis Pharmaceuticals?
As of 21-Jan-2025 the stock price of Ionis Pharmaceuticals is $32.68.
-
What is the current market cap of Ionis Pharmaceuticals?
The current market capitalization of Ionis Pharmaceuticals is $5.16B.
-
What is Ionis Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Ionis Pharmaceuticals is $803M.
-
Who are Ionis Pharmaceuticals’s competitors?
Arrowhead Pharmaceuticals, Moderna, Gilead Sciences, Nektar Therapeutics, and Dicerna Pharmaceuticals are some of the 50 competitors of Ionis Pharmaceuticals.
-
What is Ionis Pharmaceuticals’s annual earnings per share (EPS)?
Ionis Pharmaceuticals’s EPS for 12 months was -$2.44.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
